Germany – Pharmaceutical products – Open House Biologics Discount Agreements 2026 - 34 Imiglucerase
TenderZenith matches this tender's eligibility criteria against your company profile to calculate a deterministic qualification score and identify potential disqualifiers.
A structured breakdown of scope, eligibility requirements, submission steps, and key conditions — extracted directly from the official notice.
Sign in to unlock Bid Fit & AI Opportunity Intelligence
TenderZenith calculates a personalized qualification score against your company profile and extracts structured intelligence from tender documents with your 7-Day Pro Trial (No Credit Card Required).
Description & Project Overview
The health insurance companies involved pursue the goal of concluding discount agreements with all suitable pharmaceutical companies in accordance with Section 130a Paragraph 8 SGB V for the active ingredient imiglucerase. The contract is concluded as part of the TK open house procedure: individual negotiations on contract content are not conducted; uniform conditions apply. TK does not guarantee individual contractual partners any exclusivity. The contract term is a maximum of 24 months starting on January 1st, 2027. The contract ends on December 31, 2028 at the latest, regardless of the date the contract was concluded.